Trials / Conditions / Type 1 Gaucher Disease
Type 1 Gaucher Disease
6 registered clinical trials studyying Type 1 Gaucher Disease.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Terminated | A Long-Term Follow-up Study of Subjects With Gaucher Disease Who Previously Received AVR-RD-02 NCT04836377 | AVROBIO | — |
| Withdrawn | Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher D NCT03021941 | Pfizer | Phase 4 |
| Completed | A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients NCT00813865 | Amicus Therapeutics | Phase 2 |
| Terminated | A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101 NCT00875160 | Amicus Therapeutics | Phase 1 |
| Completed | A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease NCT00446550 | Amicus Therapeutics | Phase 2 |
| Completed | A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzym NCT00433147 | Amicus Therapeutics | Phase 2 |